Podiatrists in Athens, AL Accepting Medicare
3 Podiatrists found. Showing 1 - 3
 Uren,dr.k Scott Dba Athens Podiatry Center Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 910 W Hobbs St, Athens, AL 35611 Phone: 256-232-2200 |
The Foot Group P C Podiatrist - Foot Surgery Medicare: Not Enrolled in Medicare Practice Location: 205 N Malone St, Athens, AL 35611 Phone: 256-232-2009 Fax: 256-774-8211 |
North Alabama Foot Care Llc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 910 W Hobbs St, Athens, AL 35611 Phone: 256-232-2200 |
News Archive
Study focuses on nontraditional lifestyle of Retinoblastoma tumor suppressor proteins
Researchers at Michigan State University have discovered a protein that does its best work with one foot in the grave.
CT scan as effective as MRI in predicting recurrent stroke risk
New research from the University of Calgary's Hotchkiss Brain Institute (HBI) shows that using a CT (computerised tomography) scan, doctors can predict if patients who have had a transient ischemic attack (TIA) or minor stroke, with neurological symptoms such as weakness or speech issues, are at risk for another more severe stroke.
Mediterranean diet improves cardiovascular performance in patients with erectile dysfunction
The Mediterranean diet is linked to improved cardiovascular performance in patients with erectile dysfunction, according to research presented at EuroEcho-Imaging 2014 by Dr Athanasios Angelis from Greece. Patients with erectile dysfunction who had poor adherence to the Mediterranean diet had more vascular and cardiac damage.
Author Ms. Zoe Whittall to receive first Earla Dunbar Consumer Award
The Earla Dunbar Consumer Award was created to honour Earla Dunbar's legacy. Ms.Dunbar, who will be in Vancouver to present Zoe Whittall the award, was the ADAC/ACTA Consumer Advisory Committee Chairperson since its inception in 2002.
FDA grants priority review for Janssen's simeprevir
Medivir AB today announces that the U.S. Food and Drug Administration has granted Priority Review to the New Drug Application by Janssen for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease.
› Verified 6 days ago
Physical Therapists
Chiropractors
Optometrists
Speech-Language Pathologists
Occupational Therapists
Podiatrists
Audiologists